ALKS · ISSUER CIK 1520262
Alkermes plc.
Between Aug 1, 2026 and Oct 29, 2026, 5 Alkermes plc. insiders reported $0.00 of open-market purchases and $3.8M of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 6 of 7 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$3.8MInsider selling
−$3.8MNet open-market
Oct 9, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 202618:18 | Oct 8, 2026 | ALKS | SVP, Chief Financial Officer | M · Exercise | — | +9,164 | 9,164 | New | — | ||
| Oct 9, 202618:18 | Oct 8, 2026 | ALKS | SVP, Chief Financial Officer | F · Tax | $40.11 | −4,069 | 5,095 | -44% | $163K | ||
| Oct 2, 202618:22 | Oct 2, 2026 | ALKS | EVP, CLO, Alkermes, Inc. | S · Sell10b5-1 | $41.03 | −2,034 | 221,388 | -1% | −$83K | ||
| Sep 3, 202618:32 | Sep 3, 2026 | ALKS | EVP, CLO, Alkermes, Inc. | S · Sell10b5-1 | $48.01 | −2,034 | 223,422 | -1% | −$98K | ||
| Sep 1, 202619:08 | Sep 1, 2026 | ALKS | EVP R&D, Chief Medical Officer | S · Sell10b5-1 | $46.99 | −9,000 | 65,389 | -12% | −$423K | ||
| Sep 1, 202619:08 | Sep 1, 2026 | ALKS | EVP R&D, Chief Medical Officer | M · Exercise10b5-1 | $24.59 | +5,000 | 74,389 | +7% | $123K | ||
| Aug 17, 202618:53 | Aug 17, 2026 | ALKS | SVP, Chief Commercial Officer | S · Sell10b5-1 | $49.23 | −7,576 | 102,193 | -7% | −$373K | ||
| Aug 3, 202619:16 | Aug 3, 2026 | ALKS | Director | S · Sell | $50.35 | −44,472 | 15,395 | -74% | −$2.2M | ||
| Aug 3, 202619:16 | Aug 3, 2026 | ALKS | Director | M · Exercise | $46.72 | +44,472 | 59,867 | +289% | $2.1M | ||
| Aug 3, 202619:12 | Aug 3, 2026 | ALKS | EVP R&D, Chief Medical Officer | S · Sell10b5-1 | $48.58 | −9,000 | 69,389 | -11% | −$437K | ||
| Aug 3, 202619:12 | Aug 3, 2026 | ALKS | EVP R&D, Chief Medical Officer | M · Exercise10b5-1 | $24.48 | +5,000 | 78,389 | +7% | $122K | ||
| Aug 3, 202619:09 | Aug 3, 2026 | ALKS | EVP, CLO, Alkermes, Inc. | S · Sell10b5-1 | $48.58 | −2,034 | 225,456 | -1% | −$99K |